Loading clinical trials...
Loading clinical trials...
Phase II Study of Nivolumab (Group 1) and Nivolumab Plus Relatlimab (Group 2) in Patients With Locally Advanced/ Metastatic Squamous Cell Carcinoma of the Skin
Conditions
Interventions
Nivolumab
Nivolumab plus Relatlimab
Locations
7
Austria
Universitätsklinikum Graz - LKH, Klinische Abteilung für Onkologie
Graz, Austria
LKH Innsbruck Universitätsklinik für Dermatologie und Venerologie
Innsbruck, Austria
Klinikum Klagenfurt am Wörthersee
Klagenfurt, Austria
Universitätsklinik für Dermatologie und Allergologie der Paracelsus medizinischen Privatuniversität Salzburg
Salzburg, Austria
Abteilung für Haut- und Geschlechtskrankheiten, Universitätsklinikum St. Pölten Karl Landsteiner Privatuniversität für Gesundheitswissenschaften
Sankt Pölten, Austria
Med Uni Wien, Univ. Klinik für Dermatologie
Vienna, Austria
Start Date
March 6, 2017
Primary Completion Date
December 1, 2026
Completion Date
December 1, 2027
Last Updated
April 18, 2024
NCT04892849
NCT07347392
NCT06014086
NCT03894618
NCT02324608
NCT02717936
Lead Sponsor
Salzburger Landeskliniken
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions